Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue

Executive Summary

Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.

Advertisement

Related Content

Opioid Litigation: Drug Mfrs. Lose Bid To Limit Data Disclosure; First Trials Set For March
Remoxy Review Shows How Opana ER Experience Changed US FDA Thinking On New Opioid Formulations
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel